POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (5.13.2021, 12:396pm CEST, WHO):   U.S. 36,412    India 362,727    Brazil 72,715    France 18,323    Turkey 14,497    Russia 8,115    The United Kingdom 2,474    Italy 6,943    Spain 2,768    Germany 14,909    Argentina 25,976    Columbia 16,425    Poland 4,159    Iran 16,409    Mexico 1,897    Ukraine 4,538    Peru 4,869    Indonesia 4,608    Czechia 1,686    South Africa 2,759    The Netherlands 5,586    Canada 5,386    Chile 3,902    Iraq 4,666    Philippines 4,812    Romania 1,156    Sweden 2,463    Pakistan 2,881    Bangladesh 1,140    Serbia 1,125    Japan 6,927    United Arab Emirates 1,508    Malaysia 4,765    Saudi Arabia 1,020    Nepal 9,238    Greece 3,172    Croatia 1,471    Georgia 1,409    Tunisia 1,105    Bolivia 2,369    Paraguay 2,377    Costa Rica 2,236    Lithuania 1,266    Egypt 1,187    Guatemala 1,416    Uruguay 2,977    Honduras 1,130    Bahrain 1,539    Sri Lanka 1,429    Cuba 1,207    Thailand 14,887    Maldives 1,572    China 32    Singapore 16    New Zealand 1    Australia 8    South Korea 715   

U.S. study on 32,449 people shows AstraZeneca vaccine offers 100% protection against severe disease

Christian Fernsby |
AstraZeneca says advanced trial data from a U.S. study on its Covid vaccine shows it is 79 percent effective.

Article continues below




Some 32,449 people across all age groups took part in the phase three trial in the U.S., Chile and Peru, with a total of 141 cases of symptomatic Covid-19 reported.

The Oxford/AstraZeneca vaccine is 79% effective at preventing COVID-19 and offers 100% protection against severe disease, new data has shown.

The early findings from the U.S. study are just one set of information AstraZeneca must submit to the Food and Drug Administration.

The results showed that among people aged 65 and over, there was 80% protection against developing Covid-19.

The degree of effectiveness for the jab was even higher than observed in the Oxford-led clinical trials.

An independent data safety monitoring board (DSMB) also identified no safety concerns related to the vaccine.

It conducted a specific review of thrombotic events, as well as cerebral venous sinus thrombosis (CVST) – the specific type of brain blood clot that has been troubling Europe.

The DSMB found no increased risk of thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST found no cases in this trial.


What to read next

Coffee is associated with lower mortality
First genetic risk factor for erectile dysfunction identified
World-first COVID-19 alternating dose vaccine study launches in UK